Known targets — ChEMBL curated mechanism
ABL1BMXBRAFBTKCHRNA4CHRNB2CSNK1EEGFRERBB2F10FLT1FLT3FLT4IGF1RINSRITKJAK3KDRKITOPRM1PARP1PARP2PDGFRBPIK3CDRAF1RETSLC18A2TECTXKdacAdacBdacCftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 13/20 | 0.45 |
| ▸ | CRBN | Q96SW2 | 7/20 | 0.40 |
| ▸ | DDB1 | Q16531 | 6/20 | 0.40 |
| ▸ | HTR2C | P28335 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31134471 | 0.90 | DDB1 (0.47) | HTR6CRBNDDB1 | |
| SCHEMBL31134549 | 0.80 | CRBN (0.49) | HTR6CRBNDDB1HTR2C | |
| SCHEMBL31712330 | 0.77 | CRBN (0.43) | HTR6CRBNDDB1 | |
| SCHEMBL31134557 | 0.76 | DDB1 (0.50) | CRBNDDB1 | |
| SCHEMBL31342208 | 0.76 | CRBN (0.40) | CRBNDDB1 | |
| Trifluoroacetic Acid SCHEMBL31727208 | 0.75 | CRBN (0.37) | CRBNDDB1 | |
| SCHEMBL31134502 | 0.74 | CRBN (0.63) | CRBNDDB1 | |
| SCHEMBL31342558 | 0.73 | IKZF2 (0.40) | CRBNDDB1 | |
| SCHEMBL29767993 | 0.72 | CRBN (0.50) | CRBNDDB1 | |
| SCHEMBL29079566 | 0.72 | CRBN (0.50) | CRBNDDB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4688149-A1 | IRAK4 PROTACS | Astrazeneca AB (SE) | 2026-02-11 | — | — | EP | disclosed |
| US-20240374588-A1 | IRAK4 PROTACS | ASTRAZENECA AB (SE) | 2024-11-14 | — | — | US | disclosed |
| WO-2024209044-A1 | IRAK4 PROTACS | ASTRAZENECA AB (SE) | 2024-10-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240374588-A1 | IRAK4 PROTACS | IRAK4, IRAK2, IRAK3 | HTR6 3147/4885CRBN 99/4885DDB1 728/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.